Coeptis Therapeutics
(NASDAQ) COEP
This security has been delisted. This page is retained for historical reference.
COEP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowCOEP Financials
Key Financial Metrics (TTM)
Gross Margin
-2%
Operating Margin
-9%
Net Income Margin
-4%
Return on Equity
-41%
Return on Capital
-72%
Return on Assets
-27%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$2.83M
Operating Income
$13.04M
EBITDA
$11.82M
Operating Cash Flow
$8.60M
Capital Expenditure
$0.00
Free Cash Flow
$8.60M
Cash & ST Invst.
$6.35M
Total Debt
$268.88K
Coeptis Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$113.77K
+81.0%
Gross Profit
$68.61K
+287.3%
Gross Margin
60.31%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
5
N/A
Net Income
$104.28K
+96.6%
EBITDA
$3.91M
-28.6%
Quarterly Fundamentals
Net Cash
$5.16M
+131.7%
Accounts Receivable
$15.29K
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$100.00K
-94.7%
Return on Assets
-27.17%
N/A
Return on Invested Capital
-71.80%
N/A
Free Cash Flow
$1.76M
+25.7%
Operating Cash Flow
$1.76M
+25.7%